Return To Movanti

RedHill Biopharma

ROYALTY MONETIZATION

Dec 2020

MarketerRedHill Biopharma, Ltd.

MOVANTIK® (naloxegol) is a peripherally acting μ-opioid receptor antagonist that was licensed by Nektar to AstraZeneca where it was developed for the treatment of opioid-induced constipation. MOVANTIK was approved in 2014 in adult patients with chronic, non-cancer pain and is now marketed by RedHill Biopharma.

Background

HCRx purchased the royalty interests on worldwide net sales of ADYNOVATE and MOVANTIK from Nektar Therapeutics. Nektar monetized these non-strategic royalty interests in order to further fund development of its strategic pipeline.

Note: This transaction also appears in the Corporate Financing section under NEKTAR.

News

DECEMBER 22, 2020

Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Powered by  GDPR Cookie Compliance